The gut microbiome in colorectal cancer: mechanisms of carcinogenesis and emerging microbiota-targeted therapies

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally. Beyond established genetic and environmental risk factors, the gut microbiome is now recognized as a pivotal contributor to CRC pathogenesis, progression, and therapeutic response. This review synthesizes current evidence on how dysbiosis and specific pathogenic bacteria—notably Fusobacterium nucleatum (Fn), Enterotoxigenic Bacteroides fragilis (ETBF), and Escherichia coli carrying the polyketide synthase genomic island (pks+ E. coli)—may drive carcinogenesis through chronic inflammation, genotoxic metabolite production, immune evasion, and epigenetic reprogramming. Critically, we explore the microbiome’s dual role in modulating conventional therapies: Fn is linked to chemotherapy resistance and metastasis, while certain commensals may enhance radiotherapy and immunotherapy efficacy. We further evaluate emerging microbiota-targeted strategies, including fecal microbiota tra nsplantation (FMT), probiotics, prebiotics, postbiotics and precision antibiotics, which hold promise for restoring microbial balance and overcoming treatment resistance. By integrating mechanistic insights with clinical evidence, this review provides a foundation for leveraging the microbiome in CRC diagnosis, prognosis, and next-generation therapeutic approaches.

• Publication year

  2026

• Venue

  Discover Oncology

• Publication date

  2026-01-07

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1007/s12672-025-04367-1PMID 41498910PMCID 12858699
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Physiological drivers of pks+ E. coli in colorectal cancer.

  2025cited by this paper
• Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota

  2025cited by this paper
• To explore the potential combined treatment strategy for colorectal cancer: inhibition of cancer stem cells and enhancement of intestinal immune microenvironment.

  2025cited by this paper
• Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression.

  2025cited by this paper
• Prevalence of enterotoxigenic Bacteroides fragilis in patients with colorectal cancer: a systematic review and meta-analysis

  2025cited by this paper
• Unraveling the Role of Fusobacterium nucleatum in Colorectal Cancer: Molecular Mechanisms and Pathogenic Insights

  2025cited by this paper
• Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors

  2025cited by this paper
• Unravelling novel microbial players in the breast tissue of TNBC patients: a meta-analytic perspective

  2025cited by this paper
• Sodium Butyrate: A Multifaceted Modulator in Colorectal Cancer Therapy

  2025influential reference
• The SWI/SNF-related protein SMARCA3 is a histone H3K23 ubiquitin ligase that regulates H3K9me3 in cancer.

  2025cited by this paper
• Risk factors, prevention and screening of colorectal cancer: A rising problem

  2025cited by this paper
• Inflammatory Bowel Disease and Colorectal Cancer

  2024cited by this paper
• Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in colorectal cancer (Review)

  2024cited by this paper
• Microbial metabolite sodium butyrate enhances the anti-tumor efficacy of 5-fluorouracil against colorectal cancer by modulating PINK1/Parkin signaling and intestinal flora

  2024cited by this paper
• Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer.

  2024cited by this paper
• Gut microbiota protect against colorectal tumorigenesis through lncRNA Snhg9.

  2024cited by this paper
• Updated outcomes and exploratory analysis of RENMIN-215: tislelizumab plus fruquintinib and fecal microbiota transplantation in refractory microsatellite stable metastatic colorectal cancer.

  2024cited by this paper
• Adhesin RadD: the secret weapon of Fusobacterium nucleatum

  2024cited by this paper
• 1266 The gut microbiome enhances anti-PD-1 efficacy in a tumor-agnostic manner: results from a phase II trial of fecal microbiota transplantation and anti-PD-1 re-induction in MSI-H refractory cancers

  2024cited by this paper
• 607 CONSORTIUM-IO: a phase 1 study evaluating a combination of an 11-strain bacterial consortium (VE800) and nivolumab in treatment of select refractory or metastatic cancers

  2024cited by this paper
• Inhibitory Effect of Lactobacillus Paracasei CMU-Pb-L5 In a Subcutaneous Transplanted Tumor Model of Colorectal Cancer

  2024cited by this paper
• The role of microbial indole metabolites in tumor

  2024cited by this paper
• Fusobacterium nucleatum: a novel regulator of antitumor immune checkpoint blockade therapy in colorectal cancer.

  2024cited by this paper
• IDDF2024-ABS-0170 Metagenomic analyses highlight strain-level, age-independent and immunotherapy-associated microbial signatures in colorectal cancer

  2024cited by this paper
• The impact of antibiotic use in gastrointestinal tumors treated with immune checkpoint inhibitors: systematic review and meta-analysis

  2024cited by this paper
• Contribution of pks+ Escherichia coli (E. coli) to Colon Carcinogenesis

  2024cited by this paper
• Unveiling the culprit: the fusobacterium lineage that populates colorectal cancer

  2024cited by this paper
• Postbiotics of Lacticaseibacillus paracasei CECT 9610 and Lactiplantibacillus plantarum CECT 9608 attenuates store‐operated calcium entry and FAK phosphorylation in colorectal cancer cells

  2024cited by this paper
• TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer

  2024cited by this paper
• Microbiota enterotoxigenic Bacteroides fragilis-secreted BFT-1 promotes breast cancer cell stemness and chemoresistance through its functional receptor NOD1

  2024cited by this paper
• A multi-dimensional approach to unravel the intricacies of lactylation related signature for prognostic and therapeutic insight in colorectal cancer

  2024cited by this paper
• Colibactin-producing Escherichia coli enhance resistance to chemotherapeutic drugs by promoting epithelial to mesenchymal transition and cancer stem cell emergence

  2024cited by this paper
• Entero-toxigenic Bacteroides fragilis contributes to intestinal barrier injury and colorectal cancer progression by mediating the BFT/STAT3/ZEB2 pathway

  2024cited by this paper
• Postoperative Probiotics Administration Attenuates Gastrointestinal Complications and Gut Microbiota Dysbiosis Caused by Chemotherapy in Colorectal Cancer Patients

  2023cited by this paper
• Promotion of Colitis in B Cell-Deficient C57BL/6 Mice Infected with Enterotoxigenic Bacteroides fragilis

  2023cited by this paper
• Regulation of the innate immune response and gut microbiome by p53

  2023cited by this paper
• Dissecting the role of the gut microbiome and fecal microbiota transplantation in radio- and immunotherapy treatment of colorectal cancer

  2023cited by this paper
• An Update on the Pivotal Roles of Probiotics, Their Components, and Metabolites in Preventing Colon Cancer

  2023cited by this paper
• Dietary Lactobacillus rhamnosus GG extracellular vesicles enhance antiprogrammed cell death 1 (anti-PD-1) immunotherapy efficacy against colorectal cancer.

  2023cited by this paper
• Association between Probiotics and Modulation of Gut Microbial Community Composition in Colorectal Cancer Animal Models: A Systematic Review (2010–2021)

  2023cited by this paper
• Fusobacterium nucleatum promotes colorectal cancer metastasis by excretion of miR-122-5p from cells via exosomes

  2023cited by this paper
• Microbiota composition and its impact on DNA methylation in colorectal cancer

  2023cited by this paper
• Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer

  2023cited by this paper
• Short chain fatty acids prime colorectal cancer cells to activate antitumor immunity

  2023cited by this paper
• Radioimmunotherapy in colorectal cancer treatment: present and future

  2023cited by this paper
• MicroRNA-31 induced by Fusobacterium nucleatum infection promotes colorectal cancer tumorigenesis

  2023cited by this paper
• Effect of probiotic supplementation on chemotherapy- and radiotherapy-related diarrhoea in patients with cancer: an umbrella review of systematic reviews and meta-analyses

  2023cited by this paper
• Intestinal bacteria and colorectal cancer: etiology and treatment

  2023cited by this paper
• Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis

  2023cited by this paper
• Antibiotic-Therapy-Induced Gut Dysbiosis Affecting Gut Microbiota—Brain Axis and Cognition: Restoration by Intake of Probiotics and Synbiotics

  2023cited by this paper
• Efficacy of fecal microbiota transplantation in patients with anti-PD-1–resistant/refractory gastrointestinal cancers.

  2023cited by this paper
• Enterotoxigenic Bacteroides fragilis activates IL-8 expression through Stat3 in colorectal cancer cells

  2022cited by this paper
• Orally Administered Probiotics in the Prevention of Chemotherapy (± Radiotherapy)-Induced Gastrointestinal Toxicity: A Systematic Review With Meta-Analysis of Randomized Trials

  2022cited by this paper
• Antibiotic Resistance And Microbiota Response.

  2022cited by this paper
• Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy

  2022cited by this paper
• Synergistic effect of sodium butyrate and oxaliplatin on colorectal cancer

  2022cited by this paper
• The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota

  2022cited by this paper
• Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities

  2022cited by this paper
• Mechanism and strategies of immunotherapy resistance in colorectal cancer

  2022cited by this paper
• Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment

  2022cited by this paper
• Microbial short-chain fatty acids: a strategy to tune adoptive T cell therapy

  2022cited by this paper
• Western-style Diet, pks Island-Carrying Escherichia coli, and Colorectal Cancer: Analyses from Two Large Prospective Cohort Studies.

  2022cited by this paper
• Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer

  2022cited by this paper
• Preventing Colorectal Cancer through Prebiotics

  2021cited by this paper
• Fusobacterium nucleatum Promotes the Progression of Colorectal Cancer Through Cdk5-Activated Wnt/β-Catenin Signaling

  2021cited by this paper
• Radiotherapy and the gut microbiome: facts and fiction

  2021cited by this paper
• Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer

  2021cited by this paper
• Immune-related genes STIM1, ITPKC and PELI1 polymorphisms are associated with risk of colorectal cancer

  2021cited by this paper
• Association between colorectal cancer and Streptococcus gallolyticus subsp. pasteuranus (former S. bovis) endocarditis: clinical relevance and cues for microbiota science. Case report and review of the literature.

  2021cited by this paper
• Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade

  2021cited by this paper
• Lactobacillus paracasei DTA81, a cholesterol‐lowering strain having immunomodulatory activity, reveals gut microbiota regulation capability in BALB/c mice receiving high‐fat diet

  2021cited by this paper
• A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype

  2021cited by this paper
• The effect of pro/synbiotics on postoperative infections in colorectal cancer patients: A systematic review and meta-analysis.

  2021cited by this paper
• IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation

  2021cited by this paper
• Microbiome signatures of progression toward celiac disease onset in at-risk children in a longitudinal prospective cohort study

  2021cited by this paper
• Combination Therapy of Mithramycin A and Immune Checkpoint Inhibitor for the Treatment of Colorectal Cancer in an Orthotopic Murine Model

  2021cited by this paper
• The role of the bacterial microbiome in the treatment of cancer

  2021cited by this paper
• Gut Microbiota Modulation in the Context of Immune-Related Aspects of Lactobacillus spp. and Bifidobacterium spp. in Gastrointestinal Cancers

  2021cited by this paper
• Tumorigenic bacteria in colorectal cancer: mechanisms and treatments

  2021cited by this paper
• Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization

  2021cited by this paper
• Immunotherapy in colorectal cancer: current achievements and future perspective

  2021cited by this paper
• Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer

  2021cited by this paper
• Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance.

  2021cited by this paper
• Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer

  2020cited by this paper
• Enterotoxigenic Bacteroides fragilis: A Possible Etiological Candidate for Bacterially-Induced Colorectal Precancerous and Cancerous Lesions

  2020cited by this paper
• Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7

  2020cited by this paper
• Gut microbiome associated with APC gene mutation in patients with intestinal adenomatous polyps

  2020cited by this paper
• Butyrate enhances the efficacy of radiotherapy via FOXO3A in colorectal cancer patient-derived organoids

  2020cited by this paper
• FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2

  2020cited by this paper
• Colorectal Cancer Immunotherapy: Options and Strategies

  2020cited by this paper
• Streptococcus thermophilus inhibits colorectal tumorigenesis through secreting β-galactosidase.

  2020cited by this paper
• The Mechanism of Bacteroides fragilis Toxin Contributes to Colon Cancer Formation

  2020cited by this paper
• Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer

  2020cited by this paper
• MicroRNAs and Apoptosis in Colorectal Cancer

  2020cited by this paper
• The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic

  2020cited by this paper
• Enterotoxigenic Bacteroides fragilis induces the stemness in colorectal cancer via upregulating histone demethylase JMJD2B

  2020cited by this paper
• Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression

  2020cited by this paper
• Toxigenic and non-toxigenic patterns I, II and III and biofilm-forming ability in Bacteroides fragilis strains isolated from patients diagnosed with colorectal cancer

  2020cited by this paper
• Microbiome in Colorectal Cancer: How to Get from Meta-omics to Mechanism?

  2020cited by this paper
• Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer

  2020cited by this paper

• No citing papers are available for this paper.